Trial
NCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
Ohio State University
Condition
GVHD (Acute or Chronic)
Intervention
milatuzumab
Why stopped
PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19